

EXECUTIVE SUMMARY [NON-CONFIDENTIAL, NON-TECHNICAL ABSTRACT FOR PUBLIC INFORMATION OR PROGRAM PROMOTION]: State **in layman's terms** the application's broad, long-term objectives and specific aims, making reference to the potential public benefits of the project relevant to California. Do not include proprietary or confidential information. This may be distributed before the funding decision has been finalized.

An attractive goal of any drug development program is to design and synthesize a molecule that has multiple targets of application. Telmisartan is an anti-hypertensive drug of the angiotensin receptor blocker (ARB) class. Our previous work funded in part by CSUPERB has shown this drug could have positive effects in treating type II diabetes. This proposal is the investigate extending telmisartan application to potentially treat the cardiac and vascular hypertrophy and hyperplasia that accompanies cardiovascular disease.